Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations

Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations

The liposomal amphotericin B (AmB) formulation, AmBisome<sup>®</sup>, still represents the best therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy depends on the patient’s immunological status, the clinical manifestation and the endemic region. Mo...

Full description

Bibliographic Details
Main Authors: Frédéric Frézard, Marta M. G. Aguiar, Lucas A. M. Ferreira, Guilherme S. Ramos, Thais T. Santos, Gabriel S. M. Borges, Virgínia M. R. Vallejos, Helane L. O. De Morais
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Pharmaceutics
Subjects:
liposomes
amphotericin B
leishmaniasis
oral route
PEGylation
topical route
Online Access:https://www.mdpi.com/1999-4923/15/1/99

Similar Items

Similar Items